OPRK1 and major depressive disorder: Numerous clinical trials are in progress using κOR ligands to target substance use disorders and depression (Ehrich et al., 2015; Karp et al., 2014; Chavkin and Koob, 2016; Ling et al., 2016; Nasser et al., 2016).